Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative

Abstract

Voltage gated ion channels are central in defining the fundamental properties of the ventricular cardiac action potential (AP), and are also involved in the development of drug-induced arrhythmias. Many drugs can inhibit cardiac ion currents, including the Na⁺ current (I_Na), L-type Ca²⁺ current (Ica-L), and K⁺ currents (I_to, I_K1, I_Ks, and I_Kr), and thereby affect AP properties in a manner that can trigger or sustain cardiac arrhythmias. Since publication of ICH E14 and S7B over a decade ago, there has been a focus on drug effects on QT prolongation clinically, and on the rapidly activating delayed rectifier current (I_Kr), nonclinically, for evaluation of proarrhythmic risk. This focus on QT interval prolongation and a single ionic current likely impacted negatively some drugs that lack proarrhythmic liability in humans. To rectify this issue, the Comprehensive in vitro proarrhythmia assay (CiPA) initiative has been proposed to integrate drug effects on multiple cardiac ionic currents with in silico modelling of human ventricular action potentials, and in vitro data obtained from human stem cell-derived ventricular cardiomyocytes to estimate proarrhythmic risk of new drugs with improved accuracy. In this review, we present the physiological functions and the molecular basis of major cardiac ion channels that contribute to the ventricle AP, and discuss the CiPA paradigm in drug development.

Keywords: Action potential (AP); Action potential duration (APD); Cardiac action potential; Cardiac arrhythmias; Cardiac voltage-gated ion channels; Comprehensive in-vitro proarrhythmia assay (CiPA); Delayed afterdepolarization (DAD); Early afterdepolarization (EAD); I(K1); I(Ks); I(Na); I(to); In-vitro study; Patch clamp; QT prolongation; Torsade de pointes (TdP); hERG.